0001437749-18-006225.txt : 20180403 0001437749-18-006225.hdr.sgml : 20180403 20180403153755 ACCESSION NUMBER: 0001437749-18-006225 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180331 ITEM INFORMATION: Unregistered Sales of Equity Securities ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20180403 DATE AS OF CHANGE: 20180403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aeon Global Health Corp. CENTRAL INDEX KEY: 0000885074 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 141673067 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-20190 FILM NUMBER: 18733097 BUSINESS ADDRESS: STREET 1: 2225 CENTENNIAL DRIVE CITY: GAINESVILLE STATE: 2Q ZIP: 30504 BUSINESS PHONE: 888-661-0225 MAIL ADDRESS: STREET 1: 2225 CENTENNIAL DRIVE CITY: GAINESVILLE STATE: 2Q ZIP: 30504 FORMER COMPANY: FORMER CONFORMED NAME: AUTHENTIDATE HOLDING CORP DATE OF NAME CHANGE: 20010327 FORMER COMPANY: FORMER CONFORMED NAME: BITWISE DESIGNS INC DATE OF NAME CHANGE: 19930328 8-K 1 aghc20180402_8k.htm FORM 8-K aghc20180402_8k.htm

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): March 31, 2018

 

AEON GLOBAL HEALTH CORP.
(Exact name of registrant as specified in its charter)

 

COMMISSION FILE NUMBER:  0-20190

 

DELAWARE

14-1673067

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

 

 

2225 Centennial Drive

Gainesville, GA 30504

(Address and zip code of principal executive offices)

 

1-(888) 661-0225
(Registrant’s telephone number, including area code

 

___________________________________________

(Former Name, if Changed Since Last Report)

 

CHECK THE APPROPRIATE BOX BELOW IF THE FORM 8-K FILING IS INTENDED TO SIMULTANEOUSLY SATISFY THE FILING OBLIGATION OF THE REGISTRANT UNDER ANY OF THE FOLLOWING PROVISIONS:

 

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

1
 

 

Item 3.02

Unregistered Sales of Equity Securities.

 

The information disclosed in Item 5.02(e) of this Current Report on Form 8-K concerning the award of restricted stock units under the Aeon Global Health Corp. 2011 Omnibus Equity Incentive Plan, as amended, is incorporated by reference into this Item 3.02. The offers and sales of such securities have been determined to be exempt from registration under the Securities Act of 1933, as amended, in reliance on Section 4(a)(2) thereof. The issuance of the securities to the recipients were made without any form of general solicitation.

 

Item 5.02

Departure of Directors of Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

(e)      On March 31, 2018, the Company’s Board of Directors approved the grant of 40,724 restricted stock units to Mr. Hanif A. Roshan, the Company’s Chairman and Chief Executive Officer. In addition, the Board also approved the grant of an aggregate of 40,724 restricted stock units to certain other non-executive employees of the Company. All of the restricted stock units were granted under the Company’s 2011 Omnibus Equity Incentive Plan, as amended (the “2011 Plan”), and will vest on the one-year anniversary of the grant date. The Board determined that it was appropriate to grant the restricted stock units in consideration of an agreement by Mr. Roshan and the other non-executive employees to accept such compensation in lieu of cash payment of base salary for the five week period ending March 31, 2018.

 

2
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

 

 

AUTHENTIDATE HOLDING CORP.
     

 

 

 

 

 

By: /s/ Michael J. Poelking 

 

 

Name: Michael J. Poelking

 

 

Title:   Chief Financial Officer 

 Date:   April 3, 2018

 

  

 

 

3